<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03845400</url>
  </required_header>
  <id_info>
    <org_study_id>SHP643-403</org_study_id>
    <secondary_id>TAK-743-403</secondary_id>
    <nct_id>NCT03845400</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Real-world Effectiveness of Lanadelumab in Participants With Hereditary Angioedema (HAE)</brief_title>
  <acronym>EMPOWER</acronym>
  <official_title>An Observational, Non-interventional, Study of Patients With Hereditary Angioedema in the United States and Canada (EMPOWER Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda Development Center Americas, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational, prospective study aims to evaluate the real-world effectiveness of
      lanadelumab in participants with hereditary angioedema (HAE). Participant-reported attack
      diaries and patient-reported outcomes (PROs) as well as physician assessments at standard of
      care (SoC) visits will be used to describe HAE attack rates, treatment patterns, healthcare
      utilization and participant quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Hereditary Angioedema (HAE) Attacks</measure>
    <time_frame>From enrollment up to 36 months</time_frame>
    <description>Number of HAE attacks before and after lanadelumab initiation will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose of Lanadelumab Injections</measure>
    <time_frame>From enrollment up to 36 months</time_frame>
    <description>Dose of lanadelumab injections used during the study will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Lanadelumab Injections</measure>
    <time_frame>From enrollment up to 36 months</time_frame>
    <description>Frequency of lanadelumab injections during the study will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Injections Based on the Type of Administration of Lanadelumab</measure>
    <time_frame>From enrollment up to 36 months</time_frame>
    <description>Proportion of injections based on the type of administration of lanadelumab (self, caregiver, health care provider [HCP], other) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Diagnosis to Lanadelumab Initiation</measure>
    <time_frame>From enrollment up to 36 months</time_frame>
    <description>Time from diagnosis of HAE attack(s) to lanadelumab treatment initiation will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants who Discontinue Lanadelumab</measure>
    <time_frame>From enrollment up to 36 months</time_frame>
    <description>Discontinuation is defined as no documented lanadelumab use after at least 2 missing consecutive doses after the last date of injection, or documented as treatment discontinued by the physician. Proportion of participants who discontinue lanadelumab treatment will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Lanadelumab Injections Before Discontinuation per Reason for Injection</measure>
    <time_frame>From enrollment up to 36 months</time_frame>
    <description>Discontinuation is defined as no documented lanadelumab use after at least 2 missing consecutive doses after the last date of injection, or documented as treatment discontinued by the physician. Number of injections administered by participant before discontinuation per reason for injection will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hospitalizations due to Hereditary Angioedema (HAE) Attack(s)</measure>
    <time_frame>From enrollment up to 36 months</time_frame>
    <description>Number of hospitalizations due to HAE attack(s) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Emergency Room (ER) Visits due to Hereditary Angioedema (HAE) Attack(s)</measure>
    <time_frame>From enrollment up to 36 months</time_frame>
    <description>Number of emergency room (ER) visits due to HAE attack(s) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Physician Visits due to Hereditary Angioedema (HAE) Attack(s)</measure>
    <time_frame>From enrollment up to 36 months</time_frame>
    <description>Number of physician visits due to HAE attack(s) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Medications Taken at Time of Hereditary Angioedema (HAE) Attack(s)</measure>
    <time_frame>From enrollment up to 36 months</time_frame>
    <description>Number, type of rescue medications taken by the participants at the time of HAE attack(s) per the type of administration (self, caregiver, HCP, other) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hereditary Angioedema (HAE) Attack Control Score Before and After Lanadelumab Initiation, as Measured by the Angioedema Control Test (AECT)</measure>
    <time_frame>From enrollment up to 36 months (every 3 months)</time_frame>
    <description>AECT is a questionnaire and not a validated patient-reported outcome (PRO). HAE control score is evaluated as frequency of answers [very often, often, sometimes, seldom, not at all] to the following questions at record closest to enrollment date): 1. In the last 3 months, how often have you had angioedema? 2. In the last 3 months, how much has your quality of life been affected by angioedema? 3. In the last 3 months, how much has the unpredictability of your angioedema bothered you? 4. In the last 3 months, how well has your angioedema been controlled by your therapy?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angioedema Quality of Life (AE-QoL) Score</measure>
    <time_frame>From enrollment up to 36 months (every 3 months)</time_frame>
    <description>The AE-QoL is developed to measure health-related quality of life (HRQoL) impairment in participants with recurrent angioedema. It is a self-administered PRO designed for adults aged 18 years and older with a recall period of 4 weeks. There are 17 items across 4 domains: functioning (4 items), fatigue/mood (5 items), fears/shame (6 items), and food (2 items). Responses use a 5-point Likert scale ranging from 'never' to 'very often.' Global scores range from 0 to 100 and scores by domains range from 0 to 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Productivity and Activity Impairment: General Health (WPAI:GH) Score</measure>
    <time_frame>From enrollment up to 36 months (every 3 months)</time_frame>
    <description>The WPAI:GH is a generic questionnaire to measure the effect of general health and symptom severity on work productivity and regular activities during the past 7 days. It can be self- or interviewer-administered to adults aged 16 years or older. This 6-item PRO covers work (5 items) and daily activities (1 item) using yes/no or numerical answers (number of hours). WPAI:GH outcomes are expressed as impairment percentages. An overall work productivity score (health or symptom) [%0WP], is calculated by multiplying the percentage of work time spent working (health or symptom) [% WTW] by the percentage productivity at work (health or symptom) [%PW]: %0WP = %WTW * %PW.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Satisfaction (TSQM-9) Score</measure>
    <time_frame>From enrollment up to 36 months (every 3 months)</time_frame>
    <description>The TSQM is a generic questionnaire to measure participants' satisfaction with medication using yes/no and 5- or 7- point Likert scale response options. It is a self-administered PRO designed for adults aged 18 years or older with a recall period of 2 to 3 weeks, or since the last medication use. Version TSQM-9 includes 3 domains: effectiveness (3 items), convenience (3 items), and global satisfaction scale (3 items). Scores range from 0 to 100.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Hereditary Angioedema (HAE)</condition>
  <arm_group>
    <arm_group_label>Type I or Type II HAE Participants</arm_group_label>
    <description>Participants will be followed for 36 months after the enrollment date up to the time of withdrawal, lost to follow-up, death or end of follow-up (36 months) whichever comes first.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with a diagnosis of Type I or Type II HAE. The study will target 70%
        enrollment of new lanadelumab users.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Voluntarily provide written, signed, and dated (personally or via a legally-authorized
             representative) informed consent/and assent as applicable to participate in the study.
             Expression of understanding and agreement by fully informed parent(s) or legal
             guardian is required to permit the investigator to enroll a child in this study. The
             choice of the terms parental consent or parental permission in different regions may
             reflect local legal/regulatory and ethical considerations.

          -  Diagnosis of HAE Type I or Type II.

          -  Ability to use a mobile device for data collection in the study.

        Exclusion Criteria:

          -  Participation in any interventional clinical trial at the time of enrollment.

          -  Unable to provide written, signed, and dated informed consent/assent.

          -  Investigator believes that the participant is not a suitable candidate for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda Development Center Americas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takeda Development Center Americas Contact</last_name>
    <phone>+1 866 842 5335</phone>
    <email>ClinicalTransparency@takeda.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Research Center of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>205-209-4100</phone>
      <email>janderson@alabamaallergy.com</email>
    </contact>
    <investigator>
      <last_name>John Anderson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Research of Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85248</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>480-675-8982</phone>
      <email>michaelmanningmd@aol.com</email>
    </contact>
    <investigator>
      <last_name>Michael Manning</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AIRE Medical of Los Angeles</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>310-998-0060</phone>
      <email>ucladoc@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Raffi Tachdjian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asthma and Allergy Associates, PC</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>719-473-8330</phone>
      <email>dsoteres@aacos.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Soteres</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of South Florida Asthma, Allergy &amp; Immunology</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center Research Institute, Inc.</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>913-588-4682</phone>
      <email>sgierer@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Selina Gierer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute for Asthma &amp; Allergy - Chevy Chase</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>301-986-0670</phone>
      <email>hl@allergyasthma.us</email>
    </contact>
    <investigator>
      <last_name>Huamin Henry Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114-2752</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>617-726-3850</phone>
      <email>abanerji@partners.org</email>
    </contact>
    <investigator>
      <last_name>Aleena Banerji</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>734-936-5634</phone>
      <email>abaptist@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Alan Baptist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mid West Immunology Clinic</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55446</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>314-996-8339</phone>
      <email>jwedner@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>James Wedner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riverside Medical Group, Belleville</name>
      <address>
        <city>Belleville</city>
        <state>New Jersey</state>
        <zip>07109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jay M Kashkin, MD Allergy, Asthma and Immunology</name>
      <address>
        <city>Fair Lawn</city>
        <state>New Jersey</state>
        <zip>07410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>201-794-7400</phone>
      <email>floffice2@aol.com</email>
    </contact>
    <investigator>
      <last_name>Jay Kashkin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>212-659-9262</phone>
      <email>paula.busse@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Paula Busse</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>980-999-2050</phone>
      <email>djohnston@asthmanc.com</email>
    </contact>
    <investigator>
      <last_name>Douglas Johnston</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Asthma, Allergy &amp; Airway Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bernstein Clinical Research Center, LLC</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Portland Clinical Research/AAIM Care</name>
      <address>
        <city>Happy Valley</city>
        <state>Oregon</state>
        <zip>97086</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>971-220-2201</phone>
      <email>dr.fritz@aa-clinic.com</email>
    </contact>
    <investigator>
      <last_name>Stephen Fritz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Univ. Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>AARA Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>214-365-0365</phone>
      <email>lumrymd@att.net</email>
    </contact>
    <investigator>
      <last_name>William Lumry</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Calgary - Heritage Medical Research Clinic</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>McMaster University Health Sciences Center</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8S 4K1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(416) 8646060</phone>
      <email>betschels@smh.ca</email>
    </contact>
    <investigator>
      <last_name>Stephen Betschel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUM Hôtel-Dieu</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1R7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(514) 9875748</phone>
      <email>hugo.chapdelaine.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Hugo Chapdelaine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Specialisée en Allergie de la Capitale</name>
      <address>
        <city>Québec</city>
        <zip>G1V 4W2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(418) 6597741</phone>
      <email>rgagnon@csacqc.ca</email>
    </contact>
    <investigator>
      <last_name>Remi Gagnon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rafael H Zaragoza-Urdaz</name>
      <address>
        <city>San Juan</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(787) 7645715</phone>
      <email>zaragoza.urdaz@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Rafael Zaragoza-Urdaz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 18, 2019</study_first_submitted>
  <study_first_submitted_qc>February 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2019</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Shire provides access to the de-identified individual participant data for eligible studies to aid qualified researchers in addressing legitimate scientific objectives. These IPDs will be provided following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.shiretrials.com website. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.shiretrials.com/en/our-commitment-to-transparency/data-sharing-with-researchers</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

